Biomarkers in allergy and asthma:
Saved in:
| Format: | Book |
|---|---|
| Language: | English |
| Published: |
Philadelphia [u.a.]
Saunders
2007
|
| Series: | Immunology and allergy clinics of North America
27,4 |
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Physical Description: | XII S., S. 572 - 688 |
| ISBN: | 9781416050841 1416050841 |
Staff View
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV023073536 | ||
| 003 | DE-604 | ||
| 005 | 20171120 | ||
| 007 | t | ||
| 008 | 080110s2007 |||| 00||| eng d | ||
| 020 | |a 9781416050841 |9 978-1-4160-5084-1 | ||
| 020 | |a 1416050841 |9 1-4160-5084-1 | ||
| 035 | |a (OCoLC)156812248 | ||
| 035 | |a (DE-599)BVBBV023073536 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-29 | ||
| 050 | 0 | |a QR180 | |
| 082 | 0 | |a 616.2020756 |2 22 | |
| 084 | |a XD 2800 |0 (DE-625)152549:12905 |2 rvk | ||
| 084 | |a XD 3400 |0 (DE-625)152555:12905 |2 rvk | ||
| 084 | |a YB 6400 |0 (DE-625)153148:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Biomarkers in allergy and asthma |c guest ed. Rohit Katial |
| 264 | 1 | |a Philadelphia [u.a.] |b Saunders |c 2007 | |
| 300 | |a XII S., S. 572 - 688 | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Immunology and allergy clinics of North America |v 27,4 | |
| 650 | 4 | |a Allergy |x Diagnosis | |
| 650 | 4 | |a Asthma |x Diagnosis | |
| 650 | 4 | |a Asthma |x diagnosis | |
| 650 | 4 | |a Biochemical markers | |
| 650 | 4 | |a Biological Markers | |
| 650 | 4 | |a Respiratory Hypersensitivity |x diagnosis | |
| 650 | 0 | 7 | |a Biomarker |0 (DE-588)4425928-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Bronchialasthma |0 (DE-588)4069674-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Allergie |0 (DE-588)4001257-8 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Biomarker |0 (DE-588)4425928-1 |D s |
| 689 | 0 | 1 | |a Allergie |0 (DE-588)4001257-8 |D s |
| 689 | 0 | 2 | |a Bronchialasthma |0 (DE-588)4069674-1 |D s |
| 689 | 0 | |C b |5 DE-604 | |
| 700 | 1 | |a Katial, Rohit |e Sonstige |4 oth | |
| 830 | 0 | |a Immunology and allergy clinics of North America |v 27,4 |w (DE-604)BV000645505 |9 27,4 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016276658&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-016276658 | ||
Record in the Search Index
| _version_ | 1804137317943738368 |
|---|---|
| adam_text | CONTENTS
Foreword: Biomarkers in Asthma and Allergy:
Are We There Yet? ix
Rafeul Alam
Preface xi
Rohit Katial
Exhaled Nitric Oxide 571
Lora Stewart and Rohit Katial
Exhaled nitric oxide (FENO) is a noninvasive easily measurable
biomarker that is proving to be an excellent surrogate for
eosinophilic inflammation in the lungs of patients who have
asthma. Although large-scale normative data are still awaited,
preliminary studies have shown FENO to be helpful in diagnosing
and assessing severity and control for asthma. FENO levels have
also proven helpful in diagnosing and managing several other
inflammatory lung diseases.
Exhaled Breath Condensate: An Overview 587
John Hunt
Exhaled breath condensate (EBC) is a promising source of
biomarkers of lung disease. EBC is not a biomarker, but rather a
matrix in which biomarkers may be identified, in that way
equivalent to blood, sweat, tears, urine, and saliva. EBC may be
thought of either as a body fluid or as a condensate of exhaled gas.
The field of EBC research has advanced gradually, with the debates
surrounding an emerging field helping to pose questions and
gradually leading to answers. Conscientous assay technique will
likely find in EBC any substance of substantially high enough
concentration in the airway lining fluid.
Exhaled Breath Condensate pH Assays 597
John Hunt
Exhaled breath condensate (EBC) is the only currently available,
convenient, noninvasive, ethically acceptable method of assessing
airway acidity (pH), especially when it comes to repeated sampling
from acutely ill patients. It remains necessary to interpret the data
cautiously, because acid at any level in the airway can lead to EBC
acidification, and an absence of EBC acidification does not exclude
the presence of some degree of airway acidification. EBC pH
measures remain the most successful manner to date to evaluate
the role of airway acidification in respiratory disease.
Asthma Biomarkers in Sputum 607
Joseph D. Spahn
Several inflammatory cells are thought to contribute to the
pathogenesis of asthma. Among these, the eosinophil appears to
be a major effector cell. This review focuses primarily on the clinical
utility of sputum eosinophil counts in asthma. Several studies have
shown sputum eosinophils to be associated with both asthma
severity and level of asthma control. In addition, the presence of
sputum eosinophilia is strongly predictive of a favorable response
to glucocorticoid therapy. Conversely, the absence of sputum
eosinophilia is predictive of a poor response to glucocorticoid
therapy. Sputum eosinophilia also predicts asthma relapse in
subjects who have their inhaled glucocorticoid reduced or with¬
drawn. Lastly, inhaled glucocorticoid therapy can be titrated to
keep the sputum eosinophil count at or below 2%.
Tissue and BAL Based Biomarkers in Asthma 623
June Y. Zhang and Sally E. Wenzel
Asthma is a heterogeneous disease with multiple phenotypes.
There are no tissue or bronchoalveolar lavage biomarkers that are
specific for asthma. Markers associated with eosinophilic,
neutrophilic, and paucigranulocytic asthma are discussed here,
and those for remodeling. Efforts are to compare tissue and lavage
biomarkers with less invasive measures, such as sputum, serum, or
exhaled breath, to improve the treatment and management of
asthma.
Bronchoprovocation Testing in Asthma 633
Ronina A. Covar
Bronchial hyperresponsiveness (BHR) is an important feature of
asthma and is useful in diagnosis, monitoring, and prognostication.
It probably represents inherent elements of the disease process
such as genetic predisposition, airway inflammation, and airway
remodeling. Airway inflammation likely accounts for the variable
component of BHR, whereas the persistent component of BHR
correlates significantly with structural changes in the airway, such
as basement membrane thickness and epithelial damage. It might
be this component that is resistant or refractory to the effects of
available interventions. A few trials of immunomodulatory
therapy have shown considerable improvements in markers of
airway inflammation, without significantly modifying airway
reactivity. Interventions to impact the more permanent feature of
BHR are needed.
Urinary Leukotriene E4 651
Nathan Rabinovitch
Measurement of urinary leukotriene E4 (LTE4) is a sensitive and
noninvasive method of assaying total body cysteinyl leukotriene
production and changes in cysteinyl leukotriene levels in specific
microenvironments, such as the airway. Urinary LTE4 measure¬
ments can be used as sensitive biomarkers of exposure to asthma
triggers, such as air pollution and viral infections. Recent studies
suggest the potential of using urinary LTE4 concentrations as
predictors of asthma control and markers of susceptibility to
treatment with leukotriene receptor antagonists.
Pharmacogenetics of the [32-Adrenergic Receptor Gene 665
Victor E. Ortega, Gregory A. Hawkins, Stephen P. Peters,
and Eugene R. Bleecker
Asthma is a complex genetic disease with multiple genetic and
environmental determinants contributing to the observed varia¬
bility in response to common antiasthma therapies. One focus of
asthma pharmacogenetic research has been the p2-adrenergic
receptor gene (ADR(S2) and its effect on individual responses to
beta agonist therapy. Knowledge about the effects of ADR/32
variation on therapeutic responses is evolving and should not alter
current Asthma Guideline approaches, which consist of the use of
short-acting beta agonists (SABAs) for as-needed symptom-based
therapy and the use of a regular long-acting beta agonist (LABA) in
combination with inhaled corticosteroid therapy for those asth¬
matics whose symptoms are not controlled by inhaled cortico¬
steroid alone. These approaches are based upon studies showing a
consistent pharmacogenetic response to regular use of SABAs and
less consistent findings in studies evaluating LABAs. The emerging
pharmacogenetic studies are provocative and should lead to
functional studies. Meanwhile, the conflicting data concerning
LABAs may be caused by such factors as small sample sizes of
study populations and differences in experimental design.
Index 685
|
| adam_txt |
CONTENTS
Foreword: Biomarkers in Asthma and Allergy:
Are We There Yet? ix
Rafeul Alam
Preface xi
Rohit Katial
Exhaled Nitric Oxide 571
Lora Stewart and Rohit Katial
Exhaled nitric oxide (FENO) is a noninvasive easily measurable
biomarker that is proving to be an excellent surrogate for
eosinophilic inflammation in the lungs of patients who have
asthma. Although large-scale normative data are still awaited,
preliminary studies have shown FENO to be helpful in diagnosing
and assessing severity and control for asthma. FENO levels have
also proven helpful in diagnosing and managing several other
inflammatory lung diseases.
Exhaled Breath Condensate: An Overview 587
John Hunt
Exhaled breath condensate (EBC) is a promising source of
biomarkers of lung disease. EBC is not a biomarker, but rather a
matrix in which biomarkers may be identified, in that way
equivalent to blood, sweat, tears, urine, and saliva. EBC may be
thought of either as a body fluid or as a condensate of exhaled gas.
The field of EBC research has advanced gradually, with the debates
surrounding an emerging field helping to pose questions and
gradually leading to answers. Conscientous assay technique will
likely find in EBC any substance of substantially high enough
concentration in the airway lining fluid.
Exhaled Breath Condensate pH Assays 597
John Hunt
Exhaled breath condensate (EBC) is the only currently available,
convenient, noninvasive, ethically acceptable method of assessing
airway acidity (pH), especially when it comes to repeated sampling
from acutely ill patients. It remains necessary to interpret the data
cautiously, because acid at any level in the airway can lead to EBC
acidification, and an absence of EBC acidification does not exclude
the presence of some degree of airway acidification. EBC pH
measures remain the most successful manner to date to evaluate
the role of airway acidification in respiratory disease.
Asthma Biomarkers in Sputum 607
Joseph D. Spahn
Several inflammatory cells are thought to contribute to the
pathogenesis of asthma. Among these, the eosinophil appears to
be a major effector cell. This review focuses primarily on the clinical
utility of sputum eosinophil counts in asthma. Several studies have
shown sputum eosinophils to be associated with both asthma
severity and level of asthma control. In addition, the presence of
sputum eosinophilia is strongly predictive of a favorable response
to glucocorticoid therapy. Conversely, the absence of sputum
eosinophilia is predictive of a poor response to glucocorticoid
therapy. Sputum eosinophilia also predicts asthma relapse in
subjects who have their inhaled glucocorticoid reduced or with¬
drawn. Lastly, inhaled glucocorticoid therapy can be titrated to
keep the sputum eosinophil count at or below 2%.
Tissue and BAL Based Biomarkers in Asthma 623
June Y. Zhang and Sally E. Wenzel
Asthma is a heterogeneous disease with multiple phenotypes.
There are no tissue or bronchoalveolar lavage biomarkers that are
"specific" for asthma. Markers associated with eosinophilic,
neutrophilic, and paucigranulocytic asthma are discussed here,
and those for remodeling. Efforts are to compare tissue and lavage
biomarkers with less invasive measures, such as sputum, serum, or
exhaled breath, to improve the treatment and management of
asthma.
Bronchoprovocation Testing in Asthma 633
Ronina A. Covar
Bronchial hyperresponsiveness (BHR) is an important feature of
asthma and is useful in diagnosis, monitoring, and prognostication.
It probably represents inherent elements of the disease process
such as genetic predisposition, airway inflammation, and airway
remodeling. Airway inflammation likely accounts for the variable
component of BHR, whereas the persistent component of BHR
correlates significantly with structural changes in the airway, such
as basement membrane thickness and epithelial damage. It might
be this component that is resistant or refractory to the effects of
available interventions. A few trials of immunomodulatory
therapy have shown considerable improvements in markers of
airway inflammation, without significantly modifying airway
reactivity. Interventions to impact the more permanent feature of
BHR are needed.
Urinary Leukotriene E4 651
Nathan Rabinovitch
Measurement of urinary leukotriene E4 (LTE4) is a sensitive and
noninvasive method of assaying total body cysteinyl leukotriene
production and changes in cysteinyl leukotriene levels in specific
microenvironments, such as the airway. Urinary LTE4 measure¬
ments can be used as sensitive biomarkers of exposure to asthma
triggers, such as air pollution and viral infections. Recent studies
suggest the potential of using urinary LTE4 concentrations as
predictors of asthma control and markers of susceptibility to
treatment with leukotriene receptor antagonists.
Pharmacogenetics of the [32-Adrenergic Receptor Gene 665
Victor E. Ortega, Gregory A. Hawkins, Stephen P. Peters,
and Eugene R. Bleecker
Asthma is a complex genetic disease with multiple genetic and
environmental determinants contributing to the observed varia¬
bility in response to common antiasthma therapies. One focus of
asthma pharmacogenetic research has been the p2-adrenergic
receptor gene (ADR(S2) and its effect on individual responses to
beta agonist therapy. Knowledge about the effects of ADR/32
variation on therapeutic responses is evolving and should not alter
current Asthma Guideline approaches, which consist of the use of
short-acting beta agonists (SABAs) for as-needed symptom-based
therapy and the use of a regular long-acting beta agonist (LABA) in
combination with inhaled corticosteroid therapy for those asth¬
matics whose symptoms are not controlled by inhaled cortico¬
steroid alone. These approaches are based upon studies showing a
consistent pharmacogenetic response to regular use of SABAs and
less consistent findings in studies evaluating LABAs. The emerging
pharmacogenetic studies are provocative and should lead to
functional studies. Meanwhile, the conflicting data concerning
LABAs may be caused by such factors as small sample sizes of
study populations and differences in experimental design.
Index 685 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| building | Verbundindex |
| bvnumber | BV023073536 |
| callnumber-first | Q - Science |
| callnumber-label | QR180 |
| callnumber-raw | QR180 |
| callnumber-search | QR180 |
| callnumber-sort | QR 3180 |
| callnumber-subject | QR - Microbiology |
| classification_rvk | XD 2800 XD 3400 YB 6400 |
| ctrlnum | (OCoLC)156812248 (DE-599)BVBBV023073536 |
| dewey-full | 616.2020756 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.2020756 |
| dewey-search | 616.2020756 |
| dewey-sort | 3616.2020756 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02037nam a2200529 cb4500</leader><controlfield tag="001">BV023073536</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20171120 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">080110s2007 |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781416050841</subfield><subfield code="9">978-1-4160-5084-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1416050841</subfield><subfield code="9">1-4160-5084-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)156812248</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV023073536</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-29</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QR180</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.2020756</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XD 2800</subfield><subfield code="0">(DE-625)152549:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XD 3400</subfield><subfield code="0">(DE-625)152555:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YB 6400</subfield><subfield code="0">(DE-625)153148:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Biomarkers in allergy and asthma</subfield><subfield code="c">guest ed. Rohit Katial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XII S., S. 572 - 688</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Immunology and allergy clinics of North America</subfield><subfield code="v">27,4</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Allergy</subfield><subfield code="x">Diagnosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Asthma</subfield><subfield code="x">Diagnosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Asthma</subfield><subfield code="x">diagnosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biochemical markers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biological Markers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Respiratory Hypersensitivity</subfield><subfield code="x">diagnosis</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Biomarker</subfield><subfield code="0">(DE-588)4425928-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Bronchialasthma</subfield><subfield code="0">(DE-588)4069674-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Allergie</subfield><subfield code="0">(DE-588)4001257-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Biomarker</subfield><subfield code="0">(DE-588)4425928-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Allergie</subfield><subfield code="0">(DE-588)4001257-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Bronchialasthma</subfield><subfield code="0">(DE-588)4069674-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="C">b</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Katial, Rohit</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Immunology and allergy clinics of North America</subfield><subfield code="v">27,4</subfield><subfield code="w">(DE-604)BV000645505</subfield><subfield code="9">27,4</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016276658&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016276658</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV023073536 |
| illustrated | Not Illustrated |
| index_date | 2024-07-02T19:34:01Z |
| indexdate | 2024-07-09T21:10:23Z |
| institution | BVB |
| isbn | 9781416050841 1416050841 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016276658 |
| oclc_num | 156812248 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-29 |
| owner_facet | DE-355 DE-BY-UBR DE-29 |
| physical | XII S., S. 572 - 688 |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| publisher | Saunders |
| record_format | marc |
| series | Immunology and allergy clinics of North America |
| series2 | Immunology and allergy clinics of North America |
| spelling | Biomarkers in allergy and asthma guest ed. Rohit Katial Philadelphia [u.a.] Saunders 2007 XII S., S. 572 - 688 txt rdacontent n rdamedia nc rdacarrier Immunology and allergy clinics of North America 27,4 Allergy Diagnosis Asthma Diagnosis Asthma diagnosis Biochemical markers Biological Markers Respiratory Hypersensitivity diagnosis Biomarker (DE-588)4425928-1 gnd rswk-swf Bronchialasthma (DE-588)4069674-1 gnd rswk-swf Allergie (DE-588)4001257-8 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Biomarker (DE-588)4425928-1 s Allergie (DE-588)4001257-8 s Bronchialasthma (DE-588)4069674-1 s b DE-604 Katial, Rohit Sonstige oth Immunology and allergy clinics of North America 27,4 (DE-604)BV000645505 27,4 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016276658&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Biomarkers in allergy and asthma Immunology and allergy clinics of North America Allergy Diagnosis Asthma Diagnosis Asthma diagnosis Biochemical markers Biological Markers Respiratory Hypersensitivity diagnosis Biomarker (DE-588)4425928-1 gnd Bronchialasthma (DE-588)4069674-1 gnd Allergie (DE-588)4001257-8 gnd |
| subject_GND | (DE-588)4425928-1 (DE-588)4069674-1 (DE-588)4001257-8 (DE-588)4143413-4 |
| title | Biomarkers in allergy and asthma |
| title_auth | Biomarkers in allergy and asthma |
| title_exact_search | Biomarkers in allergy and asthma |
| title_exact_search_txtP | Biomarkers in allergy and asthma |
| title_full | Biomarkers in allergy and asthma guest ed. Rohit Katial |
| title_fullStr | Biomarkers in allergy and asthma guest ed. Rohit Katial |
| title_full_unstemmed | Biomarkers in allergy and asthma guest ed. Rohit Katial |
| title_short | Biomarkers in allergy and asthma |
| title_sort | biomarkers in allergy and asthma |
| topic | Allergy Diagnosis Asthma Diagnosis Asthma diagnosis Biochemical markers Biological Markers Respiratory Hypersensitivity diagnosis Biomarker (DE-588)4425928-1 gnd Bronchialasthma (DE-588)4069674-1 gnd Allergie (DE-588)4001257-8 gnd |
| topic_facet | Allergy Diagnosis Asthma Diagnosis Asthma diagnosis Biochemical markers Biological Markers Respiratory Hypersensitivity diagnosis Biomarker Bronchialasthma Allergie Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016276658&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000645505 |
| work_keys_str_mv | AT katialrohit biomarkersinallergyandasthma |